We can’t show the full text here under this license. Use the link below to read it at the source.
Real-World Weight Loss Among Patients Initiating Semaglutide 2.4 mg and Enrolled in WeGoTogether, a Digital Self-Support Application
Weight Loss in Patients Using Semaglutide 2.4 mg and a Digital Self-Support App
AI simplified
Abstract
Patients experienced an average weight loss of 20.4% at 24 months while using and the WeGoTogether patient support program.
- The study included 8177 adults with overweight or obesity, with 93.0% having a BMI of 30.0 kg/m or higher.
- Weight loss averaged 13.4% at 6 months, 17.6% at 12 months, 20.3% at 18 months, and 20.4% at 24 months.
- Proportions of patients achieving at least 20% weight loss were 13.1%, 43.3%, 52.5%, and 50.5% at 6, 12, 18, and 24 months, respectively.
- Similar weight loss results were observed in patients with a BMI of 30.0 kg/m or higher.
AI simplified
Key numbers
-20.4%
Mean Percent Weight Loss
Percent weight loss at 24 months among patients with BMI ≥ 25.0 kg/m.
50.5%
Proportion Achieving ≥ 20% Weight Loss
Proportion of patients at 24 months.
8177
Total Patients in Study
Total number of patients who met eligibility criteria.